4221 North 203rd Street Suite 100,
Elkhorn , NE, 68130
Elkhorn , NE, 68130
Summary
The fund seeks capital appreciation in the long term by investing in companies across any size in the United States.
The investment process is relies on fundamental analysis to identify companies in healthcare and life sciences companies.
Healthcare and life sciences companies include those companies that derive or are expected to derive 50% or more of their revenue from healthcare and life science products and services inc More
Link
Directors
Sep 13, 2023- Stephen P. Lachenauer
- Jerry Szilagyi
- Tobias Caldwell
- Tiberiu Weisz
Chief Compliance Officer
- Frederick J. Schmidt
Fund Manager(s)
Price
- 52-Week High/Low
- $40.29 - $32.99
- Turnover
- 62%
- Expense Ratio
- 1.31%
Company Name |
Holding |
Celldex Therapeutics Inc. | 4.01 % |
Mirum Pharmaceuticals Inc. | 4 % |
Vaxcyte Inc | 3.87 % |
Insmed Inc | 3.14 % |
Aura Biosciences Inc. | 3.04 % |
Guardant Health Inc | 2.91 % |
Collegium Pharmaceutical Inc. | 2.87 % |
Axsome Therapeutics Inc. | 2.78 % |
Sarepta Therapeutics Inc | 2.51 % |
Lexeo Therapeutics Inc | 2.32 % |
More | 2.32 % |
Documents
Performance
YTD
-
3 Year
1.38%
5 Year
-19.24%
Best
61.81%
2013
Worst
-25.23%
2021
2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
---|---|---|---|---|---|---|---|---|---|---|
Q1 | - | 4.8% | -1.6% | -23.2% | -16.9% | -23.6% | 34.6% | 4.8% | 12.9% | -23.7% |
Q2 | - | -4.5% | 14.9% | -14.9% | 2% | 37.7% | -0.3% | 19.8% | 3.9% | 3% |
Q3 | - | - | -11.6% | 13.8% | -6.2% | -1.2% | -18.8% | 8.7% | 18.6% | 18.4% |
Q4 | - | - | 14.3% | 8.1% | -6% | 27.5% | 43.4% | -20.8% | 3.3% | -9.8% |
J | F | M | A | M | J | J | A | S | O | N | D | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025 | - | - | - | - | - | - | - | - | - | - | - | - |
2024 | -2.6% | 7.8% | -0.2% | -12.3% | - | - | - | - | - | - | - | - |
2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | ||
---|---|---|---|---|---|---|---|---|---|---|---|
0% | -1% | 11% | -20% | -25% | 33% | 55% | -0% | 46% | -16% |
Alpha
2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
---|---|---|---|---|---|---|---|---|---|---|
ETIHX | - | -1% | 11% | -20% | -25% | 33% | 55% | -0% | 46% | -16% |
S&P 500 | - | - | - | -21% | 27% | 16% | 29% | -6% | 19% | 10% |
Alpha | - | -1% | 11% | 2% | -52% | 16% | 27% | 6% | 26% | -26% |